#1 Clinical Trials Search in Europe

Filgrastim

Filgrastim, a recombinant granulocyte colony-stimulating factor (G-CSF), is being extensively studied in clinical trials for its potential to improve outcomes in cancer patients undergoing chemotherapy. This article explores how Filgrastim is being used to manage neutropenia, enhance stem cell mobilization, and potentially promote collateral growth in coronary artery disease.

Table of Contents

What is Filgrastim?

Filgrastim is a medication that belongs to a class of drugs called granulocyte colony-stimulating factors (G-CSF). It is also known by several other names, including:

  • Neupogen
  • GCSF
  • rG-CSF (recombinant Granulocyte Colony Stimulating Factor)
  • Tbo-filgrastim
  • ZARZIO

These names may be used interchangeably in medical settings, but they all refer to the same medication or very similar versions of it[1][2].

How Filgrastim Works

Filgrastim works by stimulating the bone marrow to produce more white blood cells, specifically a type called neutrophils. Neutrophils are crucial for fighting infections in the body. When a person has a low neutrophil count (a condition called neutropenia), they are at higher risk for infections[1].

The medication mimics a natural protein in your body that tells the bone marrow to make more of these important cells. By increasing the number of neutrophils, Filgrastim helps to strengthen the body’s immune system and its ability to fight off infections[3].

Medical Uses of Filgrastim

Filgrastim is used in several medical situations:

  1. Cancer Treatment: It’s commonly used in patients undergoing chemotherapy. Chemotherapy can lower white blood cell counts, and Filgrastim helps to boost them back up, reducing the risk of infections[1].
  2. Bone Marrow Transplants: Filgrastim can help stimulate the growth of new white blood cells after a bone marrow transplant[4].
  3. Stem Cell Collection: It’s used to mobilize stem cells from the bone marrow into the bloodstream, where they can be collected for transplantation procedures[2].
  4. Severe Chronic Neutropenia: In patients with persistently low neutrophil counts due to various conditions, Filgrastim can help maintain a healthier white blood cell level[1].
  5. HIV/AIDS: It may be used in HIV patients to help maintain neutrophil counts and reduce the risk of bacterial infections.

How Filgrastim is Administered

Filgrastim is typically given as an injection under the skin (subcutaneously) or into a vein (intravenously). The dosage and duration of treatment can vary depending on the specific medical condition and individual patient factors[1].

For example:

  • In cancer patients receiving chemotherapy, it might be given daily for up to two weeks following each chemotherapy cycle.
  • For stem cell mobilization, it might be given for 4-5 days before the collection procedure[2].
  • In patients with chronic conditions, it may be given on a long-term basis.

The exact schedule will be determined by your healthcare provider based on your specific needs and response to the medication.

Potential Side Effects

Like all medications, Filgrastim can cause side effects. Common side effects may include:

  • Bone pain
  • Headache
  • Nausea
  • Skin rash
  • Fatigue
  • Fever

Most side effects are mild and manageable. However, in rare cases, more serious side effects can occur. It’s important to report any unusual symptoms to your healthcare provider[1].

Ongoing Research and Future Potential

Researchers continue to explore new uses for Filgrastim. Some areas of ongoing research include:

  • Cardiovascular Disease: Studies are investigating whether Filgrastim can help promote the growth of new blood vessels in patients with coronary artery disease[5].
  • Fertility Treatment: Some research is looking at whether Filgrastim could help improve outcomes in certain fertility treatments[6].
  • Premature Ovarian Insufficiency: There’s ongoing research to see if Filgrastim could help improve ovarian function in women with this condition[7].
  • Severe Skin Reactions: Studies are investigating the potential use of Filgrastim in treating severe drug-induced skin reactions[8].

These areas of research are still in early stages, and more studies are needed to determine if Filgrastim will be effective for these conditions.

Aspect Details
Primary Use Prevention and treatment of chemotherapy-induced neutropenia in cancer patients
Administration Subcutaneous injection, typically daily for 5-10 days following chemotherapy
Key Benefits Reduces risk of infection, allows maintenance of chemotherapy dose intensity
Common Side Effects Bone pain, fatigue, mild flu-like symptoms
Emerging Applications Stem cell mobilization, potential use in coronary artery disease, fertility treatments
Monitoring Regular blood tests to check neutrophil counts and other blood cell levels
Cost Considerations Significant cost per injection, potential for substantial savings with optimized dosing schedules

FAQ

  • What is Filgrastim and how does it work? Filgrastim is a man-made version of granulocyte colony-stimulating factor (G-CSF), a protein that stimulates the bone marrow to produce white blood cells. It works by promoting the growth and development of neutrophils, a type of white blood cell crucial for fighting infections.
  • Why is Filgrastim used in cancer treatment? Filgrastim is primarily used to reduce the risk of infection in cancer patients undergoing chemotherapy. It helps to prevent or treat neutropenia, a condition where the number of neutrophils in the blood becomes dangerously low, making patients more susceptible to infections.
  • How is Filgrastim administered? Filgrastim is typically administered as a subcutaneous injection. The dosage and duration can vary depending on the specific treatment protocol, but it's often given daily for several days following a chemotherapy cycle.
  • Are there any side effects associated with Filgrastim? Common side effects of Filgrastim can include bone pain, fatigue, and mild flu-like symptoms. In rare cases, more serious side effects such as spleen enlargement or allergic reactions may occur. It's important to report any unusual symptoms to your healthcare provider.
  • Can Filgrastim be used for purposes other than cancer treatment? Yes, Filgrastim is being studied for various other applications. For example, it's being investigated for its potential to mobilize stem cells for collection in healthy donors, and for possible benefits in treating coronary artery disease by promoting collateral growth.

Ongoing Clinical Trials on Filgrastim

  • Study to Improve Tolerance of Sacituzumab Govitecan with Loperamide and Filgrastim in Patients with Advanced Triple-Negative or Luminal Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium France Germany Italy The Netherlands +3

  • Study of Pembrolizumab and Chemotherapy for Patients with Triple Negative Breast Cancer

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Ireland Italy Poland Portugal +2

  • Study Comparing Subcutaneous Pembrolizumab with Hyaluronidase to Intravenous Pembrolizumab and Chemotherapy for First-line Treatment of Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France Hungary Poland Romania Spain

Glossary

  • Neutropenia: A condition characterized by an abnormally low count of neutrophils, a type of white blood cell important for fighting infections. It's a common side effect of chemotherapy.
  • Febrile Neutropenia: A serious condition where a patient with neutropenia develops a fever, indicating a possible infection. It often requires immediate medical attention and hospitalization.
  • Granulocyte Colony-Stimulating Factor (G-CSF): A protein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. Filgrastim is a synthetic version of this protein.
  • Stem Cell Mobilization: The process of moving stem cells from the bone marrow into the bloodstream, where they can be collected for transplantation or other therapeutic purposes.
  • Absolute Neutrophil Count (ANC): A measure of the number of neutrophils in the blood, used to assess the severity of neutropenia and guide treatment decisions.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. This helps determine the appropriate dosing and timing of medication.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and the relationship between drug concentration and effect.
  • Antral Follicle Count (AFC): A measure of the number of small follicles in the ovaries, used as an indicator of ovarian reserve and fertility potential.
  • Anti-Müllerian Hormone (AMH): A hormone produced by the ovaries that is used as a marker of ovarian reserve and can help predict response to fertility treatments.
  • Premature Ovarian Insufficiency (POI): A condition where the ovaries stop functioning normally before the age of 40, leading to reduced fertility and hormonal changes.

References

  1. https://clinicaltrials.gov/study/NCT02190721
  2. https://clinicaltrials.gov/study/NCT03029000
  3. https://clinicaltrials.gov/study/NCT03498248
  4. https://clinicaltrials.gov/study/NCT00228813
  5. https://clinicaltrials.gov/study/NCT00596479
  6. https://clinicaltrials.gov/study/NCT03023774
  7. https://clinicaltrials.gov/study/NCT06117982
  8. https://clinicaltrials.eu/trial/study-on-filgrastim-for-patients-with-severe-bullous-drug-eruptions-lyell-and-stevens-johnson-syndromes/